Intellia Therapeutics, Inc.

NASDAQ:NTLA

Biotechnology

Healthcare
$9.77 +0.14%

+$0.02 today

Market cap
$1.37B
Beta
1.81
P/E (TTM)
-4.6
EPS (TTM)
-$3.33
52W Low $7.95High $28.25

Volume 7.23M

Average 6.11M

NTLA Other Stockholders Equity

Equity items not reported separately, such as additional paid-in capital or treasury stock.

Intellia Therapeutics, Inc.NASDAQ: NTLA

Other Stockholders Equity · Q1 FY2026 · quarter ended Mar 2026

Other stockholders equity remains negative

Q1 FY2026 other stockholders equity was $0, compared with $0 a year earlier.

Context

  • Other stockholders equity amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Other stockholders equity increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Other Stockholders Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Stockholders Equity history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Other Stockholders Equity vs competitors

How NTLA compares with its peers on the latest reported figures

  • NTLA's Mar 2026 other stockholders equity of $0 is the 2nd highest of the 10 companies compared; the peer median is $0.
  • Other stockholders equity amounts to 0.0% of total assets for NTLA, versus a peer median of 0.0%.
NTLA Competitors Peer median
Other Stockholders Equity for NTLA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CRSPCRISPR Therapeutics AGSep 2026$3.93B ——153.8%
NTLAIntellia Therapeutics, Inc.Mar 2026$0 ——0.0%
BEAMBeam Therapeutics Inc.Jun 2026$0 ——0.0%
QUREuniQure N.V.Mar 2026$0 ——0.0%
PGENPrecigen, Inc.Jun 2026$0 ——0.0%
MGTXMeiraGTx Holdings plcMar 2026$0 ——0.0%
SANASana Biotechnology, Inc.Mar 2026$0 ——0.0%
EDITEditas Medicine, Inc.Mar 2026$0 ——0.0%
RCKTRocket Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
CRBUCaribou Biosciences, Inc.Mar 2026$0 ——0.0%
Peer median (excluding NTLA) $0——0.0%

Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents123.41M523.51M226.75M189.18M155.46M
Short-term Investments625.28M669.12M685.48M412.33M294.42M
Net Receivables2.03M3.77M36.46M8.52M9.47M
Inventory00000
Other Current Assets020.41M49.65M29.83M68.36M
Total Current Assets769.3M1.22B998.33M639.86M527.71M
Property, Plant & Equipment (Net)100.11M161M148.14M246.67M123.63M
Goodwill00000
Intangible Assets00000
Long-term Investments425.05M142.32M154.51M44.26M35.54M
Tax Assets00000
Other Non-current Assets000260.22M155.25M
Total Non-current Assets525.16M303.32M302.65M551.15M314.42M
Total Assets1.29B1.52B1.3B1.19B842.13M
Account Payables9.65M5.15M7.45M14.59M20.25M
Short-term Debt00000
Tax Payables00000
Deferred Revenue63.76M43.84M22.14M20.66M7.29M
Other Current Liabilities20.36M21.78M6.89M24.08M23.07M
Total Current Liabilities125.83M126.55M115.21M110.85M103.88M
Long-term Debt000066.85M
Deferred Tax Liabilities00(38.85M)00
Deferred Revenue (Non-current)63.48M19.93M38.85M18.26M0
Other Non-current Liabilities024.03M38.85M00
Total Non-current Liabilities128.39M157.98M135.6M208.21M66.85M
Total Liabilities254.22M284.53M250.81M319.06M170.73M
Common Stock7K9K9K10K12K
Retained Earnings(703M)(1.18B)(1.66B)(2.18B)(2.59B)
Accumulated OCI(2.63M)(7.46M)(2.26M)605K1.03M
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.04B1.24B1.05B871.96M671.39M
Total Debt74.02M130.7M115.35M210.2M93.33M
Net Debt(49.38M)(392.8M)(111.4M)21.02M(62.14M)

Intellia Therapeutics, Inc.

NASDAQ:NTLA

Intrinsic Alpha fair value

Locked

Current Price

$9.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.